Skip to main content

Table 2 Treatment outcomes for ART-naïve and ZDVm-experienced women starting therapeutic ART in 2000-2009

From: Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women

Variable ZDVm-experienced N = 91 ART-naïve N = 1937 Unadjusted/Adjusted* 95% CI p-value
Death/AIDS event within 1 year, n (%) 1 (1.1) 92 (4.8) 0.45 0.16-1.19 0.11
     0.59 0.22-1.60 0.30
CD4 cell count change at 6 months, median cells/mm3 (IQR)a 106 (41–171) 106 (34–197) −0.66 −49.5-24.6 0.51
     −0.68 −44.6-29.2 0.68
CD4 cell count change at 12 months, median cells/mm3 (IQR)b 153 (61–233) 160 (70–256) −1.2 −71.3-18.1 0.24
     −0.83 −63.3-25.7 0.41
Virological suppression at 6 months, n (%)c 53 (74.7) 1115 (74.4) 1.01 0.59-1.75 0.96
     1.00 0.56-1.73 0.97
Virological suppression at 12 months, n (%)d 52 (78.8) 1108 (77.8) 1.06 0.58-1.94 0.85
     1.06 0.57-1.96 0.86
Achieved virological suppression within 1 year, n (%)e 75 (86.2) 1408 (84.7) 1.30 1.03-1.64 0.03
     1.28 1.01-1.62 0.04
Virological rebound among those achieving virological suppression within 6 months, n (%)f 16 (22.9) 197 (16.6) 1.54 0.93-2.57 0.10
     1.51 0.90-2.53 0.12
  1. aZDVm: n = 59 and ART-naïve: n = 1272; bZDVm: n = 58 and ART-naïve: n = 1192; cZDVm: n = 71 and ART-naïve: n = 1499; dZDVm: n = 66 and ART-naïve: n = 1424; eZDVm: n = 70 and ART-naïve: n = 1189; fZDVm: n = 70 and ART-naïve: n = 1189.
  2. Estimates are odds ratios (viral suppression at 6 and 12 months), hazard ratios (death/AIDS event, virological suppression within 1 year, virological rebound) or difference in medians (CD4 cell count change at 6 and 12 months).
  3. *Variables adjusted for are: age at start of ART, exposure group, ethnicity, time since HIV-diagnosis, year of starting ART, previous AIDS event, baseline viral load category, baseline CD4 count category and hepatitis B/C co-infection.